[go: up one dir, main page]

RU2017129455A - DESIGNED IMMUNE CELLS WITH T-CELL RECEPTOR KNOCKED WITH CHIMERIC ANTIGENE RECEPTORS, BINDING WITH CD123, FOR TREATMENT OF RESIDUAL ACCIDENTS - Google Patents

DESIGNED IMMUNE CELLS WITH T-CELL RECEPTOR KNOCKED WITH CHIMERIC ANTIGENE RECEPTORS, BINDING WITH CD123, FOR TREATMENT OF RESIDUAL ACCIDENTS Download PDF

Info

Publication number
RU2017129455A
RU2017129455A RU2017129455A RU2017129455A RU2017129455A RU 2017129455 A RU2017129455 A RU 2017129455A RU 2017129455 A RU2017129455 A RU 2017129455A RU 2017129455 A RU2017129455 A RU 2017129455A RU 2017129455 A RU2017129455 A RU 2017129455A
Authority
RU
Russia
Prior art keywords
seq
tcr
car
immune cells
domain
Prior art date
Application number
RU2017129455A
Other languages
Russian (ru)
Other versions
RU2017129455A3 (en
Inventor
Барбра Джонсон САСУ
Арвинд РАДЖПАЛ
Филипп ДЮШАТО
Александре ДЖЮЛЛЕРА
Джулиен ВАЛТОН
Роман Галетто
Матьё СИМОН
Original Assignee
Селлектис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2015/055848 external-priority patent/WO2015140268A1/en
Application filed by Селлектис filed Critical Селлектис
Publication of RU2017129455A publication Critical patent/RU2017129455A/en
Publication of RU2017129455A3 publication Critical patent/RU2017129455A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/1031—Investigating individual particles by measuring electrical or magnetic effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1028—Sorting particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)

Claims (24)

1. CD123-специфичный химерный антигенный рецептор (CD123 CAR), включающий1. CD123-specific chimeric antigenic receptor (CD123 CAR), including - внеклеточный домен, включающий внеклеточный лиганд-связывающий домен, последовательно включающий необязательно гуманизированный линкер VH, предпочтительно линкер последовательности (GGGGS)n с n=1-4, предпочтительно n=3, и необязательно гуманизированный шарнир VL,an extracellular domain comprising an extracellular ligand binding domain sequentially comprising an optionally humanized VH linker, preferably a sequence linker (GGGGS) n with n = 1-4, preferably n = 3, and an optionally humanized VL hinge, - трансмембранный домен и- transmembrane domain and - цитоплазматический домен,- cytoplasmic domain, - по меньшей мере, один эпитоп, специфичный в отношении моноклонального антитела (мимеотопа).- at least one epitope specific for a monoclonal antibody (mimeotope). 2. CD123 CAR по п. 1, включающий2. CD123 CAR according to claim 1, including - внеклеточный домен, включающий внеклеточный лиганд-связывающий домен, содержащий последовательно VH, выбранный из SEQ ID NO 12, SEQ ID NO 24, SEQ ID NO 25, SEQ ID NO 26, ID NO 27, SEQ ID NO 28, SEQ ID NO 29 и SEQ ID NO 30, необязательно гуманизированный линкер, предпочтительно линкер последовательности (GGGGS)n с n=1-4, предпочтительно n=3, и VL, выбранный из SEQ ID NO 11, SEQ ID NO 18, SEQ ID NO 19, SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 22 и SEQ ID NO 23, необязательно гуманизированный шарнир VL,- extracellular domain, including an extracellular ligand binding domain, containing sequentially VH selected from SEQ ID NO 12, SEQ ID NO 24, SEQ ID NO 25, SEQ ID NO 26, ID NO 27, SEQ ID NO 28, SEQ ID NO 29 and SEQ ID NO 30, an optionally humanized linker, preferably a sequence linker (GGGGS) n with n = 1-4, preferably n = 3, and a VL selected from SEQ ID NO 11, SEQ ID NO 18, SEQ ID NO 19, SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 22 and SEQ ID NO 23, an optional humanized VL hinge, - трансмембранный домен из CD8alpha и- transmembrane domain from CD8alpha and - цитоплазматический домен, включающий сигнальный домен CD3zeta и костимулирующий домен из 4-1ВВ.- a cytoplasmic domain, including the CD3zeta signal domain and a costimulatory domain of 4-1BB. 3. CD123 CAR по п. 1 или 2, не включающий последовательности, идентичной CD28 NP_006130.1 человека.3. CD123 CAR according to claim 1 or 2, not including a sequence identical to CD28 NP_006130.1 person. 4. CD123 CAR по любому из пп. 1-3, включающий последовательность, выбранную из SEQ ID NO 172, SEQ ID NO 173, SEQ ID NO 174, SEQ ID NO 175, SEQ ID NO 176, SEQ ID NO 177, SEQ ID NO 178, SEQ ID NO 179, SEQ ID NO 180, SEQ ID NO 181, SEQ ID NO 182, SEQ ID NO 183, SEQ ID NO 184, SEQ ID NO 185, SEQ ID NO 186 и SEQ ID NO 187, необязательно дополнительно включающий, по меньшей мере, одну SEQ ID NO 161.4. CD123 CAR according to any one of paragraphs. 1-3, comprising a sequence selected from SEQ ID NO 172, SEQ ID NO 173, SEQ ID NO 174, SEQ ID NO 175, SEQ ID NO 176, SEQ ID NO 177, SEQ ID NO 178, SEQ ID NO 179, SEQ ID NO 180, SEQ ID NO 181, SEQ ID NO 182, SEQ ID NO 183, SEQ ID NO 184, SEQ ID NO 185, SEQ ID NO 186 and SEQ ID NO 187, optionally further comprising at least one SEQ ID NO 161. 5. CD123 CAR по любому из пп. 1-4, в котором указанный внеклеточный домен включает, по меньшей мере, один эпитоп, специфичный в отношении моноклонального антитела (мимеотопа), выбранный из SEQ ID NO 161, SEQ ID NO 162, SEQ ID NO 163, SEQ ID NO 164, SEQ ID NO 165, SEQ ID NO 166, SEQ ID NO 167, SEQ ID NO 168, SEQ ID NO 169 и SEQ ID NO 170, предпочтительно SEQ ID NO 161 и SEQ ID NO 169.5. CD123 CAR according to any one of paragraphs. 1-4, in which the specified extracellular domain includes at least one epitope specific for a monoclonal antibody (mimeotope) selected from SEQ ID NO 161, SEQ ID NO 162, SEQ ID NO 163, SEQ ID NO 164, SEQ ID NO 164, SEQ ID NO 165, SEQ ID NO 166, SEQ ID NO 167, SEQ ID NO 168, SEQ ID NO 169 and SEQ ID NO 170, preferably SEQ ID NO 161 and SEQ ID NO 169. 6. CD123 CAR по любому из пп. 1-5, включающий последовательность, выбранную из SEQ ID NO 160, SEQ ID NO 171, SEQ ID NO 188, SEQ ID NO 189, SEQ ID NO 190, SEQ ID NO 191, SEQ ID NO 192, SEQ ID NO 193, SEQ ID NO 194, SEQ ID NO 195, SEQ ID NO 196 и SEQ ID NO 197.6. CD123 CAR according to any one of paragraphs. 1-5, comprising a sequence selected from SEQ ID NO 160, SEQ ID NO 171, SEQ ID NO 188, SEQ ID NO 189, SEQ ID NO 190, SEQ ID NO 191, SEQ ID NO 192, SEQ ID NO 193, SEQ ID NO 194, SEQ ID NO 195, SEQ ID NO 196 and SEQ ID NO 197. 7. Полинуклеотид, кодирующий CD123 специфичный химерный антигенный рецептор (CD123 CAR) по любому из пп. 1-6.7. Polynucleotide encoding a CD123 specific chimeric antigenic receptor (CD123 CAR) according to any one of paragraphs. 1-6. 8. Вектор экспрессии, включающий полинуклеотид по п. 7.8. An expression vector comprising a polynucleotide according to claim 7. 9. Вектор экспрессии, включающий каркас молекулы и, по меньшей мере, одну последовательность, кодирующую какой-либо из CD123 по любому из пп. 1-6.9. An expression vector comprising a molecule framework and at least one sequence encoding any one of CD123 according to any one of claims. 1-6. 10. Вектор экспрессии, включающий каркас, промотор EF1, открытую рамку считывания RQR8 (RQR8 ORF), последовательность, кодирующую какой-либо CD123 CAR по любому из пп. 1-6.10. An expression vector comprising a framework, an EF1 promoter, an RQR8 open reading frame (RQR8 ORF), a sequence encoding any CD123 CAR according to any one of claims. 1-6. 11. Сконструированные иммунные клетки с нокаутом (КО) рецептора Т-клеток (TCR) или с нокаутом (КО) TCR и дезоксицитидинкиназы (dCK), экспрессирующие на мембране клеточной поверхности CD123 CAR по любому из пп. 1-611. Designed immune cells with knockout (KO) of the T-cell receptor (TCR) or knockout (KO) TCR and deoxycytidine kinase (dCK) expressing on the cell surface membrane CD123 CAR according to any one of claims. 1-6 12. Сконструированные иммунные клетки с TCR КО или с TCR KO и dCK КО, включающие полинуклеотид, кодирующий CD123-специфичный химерный антигенный рецептор (CD123 CAR) по любому из пп. 1-6.12. Designed immune cells with TCR KO or TCR KO and dCK KO, comprising a polynucleotide encoding a CD123-specific chimeric antigenic receptor (CD123 CAR) according to any one of paragraphs. 1-6. 13. TCR KO или TCR KO и dCK KO CD123 CAR-экспрессирующие сконструированные иммунные клетки по п. 4, дополнительно экспрессирующие домен смерти на поверхности клетки.13. TCR KO or TCR KO and dCK KO CD123 CAR-expressing engineered immune cells according to claim 4, further expressing a death domain on the cell surface. 14. TCR KO или TCR KO и dCK KO CD123 CAR-экспрессирующие сконструированные иммунные клетки по любому из пп. 11-13, в которых экспрессия, по меньшей мере, одного белка МНС подавлена.14. TCR KO or TCR KO and dCK KO CD123 CAR-expressing engineered immune cells according to any one of claims. 11-13, in which the expression of at least one MHC protein is suppressed. 15. TCR KO или TCR KO и dCK KO CD123 CAR-экспрессирующие сконструированные иммунные клетки по любому из пп. 11-14 для применения в терапии.15. TCR KO or TCR KO and dCK KO CD123 CAR-expressing engineered immune cells according to any one of claims. 11-14 for use in therapy. 16. TCR KO или TCR KO и dCK KO CD123 CAR-экспрессирующие сконструированные иммунные клетки по п. 15 для применения в лечении острого миелоидного лейкоза (ОМЛ), предпочтительно устойчивого/рецидивирующего ОМЛ, BPDNL или для применения во время или перед трансплантацией костного мозга.16. TCR KO or TCR KO and dCK KO CD123 CAR-expressing engineered immune cells according to claim 15 for use in the treatment of acute myeloid leukemia (AML), preferably persistent / recurrent AML, BPDNL, or for use during or before bone marrow transplantation. 17. TCR KO или TCR KO и dCK KO CD123 CAR-экспрессирующие сконструированные иммунные клетки по п. 15 для применения в качестве лекарственного средства для лечения лимфопролиферативного заболевания, более предпочтительно лейкоза или лимфомы, или для лечения заболевания, выбранного из группы, включающей острый миелоидный лейкоз, хронический миелоидный лейкоз, миелодиспластический синдром, острый лимфоидный лейкоз, хронический лимфоидный лейкоз и миелодиспластический синдром и новообразование из бластных плазмоцитоидных дендритных клеток (BPDNL).17. TCR KO or TCR KO and dCK KO CD123 CAR-expressing engineered immune cells according to claim 15 for use as a medicament for treating lymphoproliferative disease, more preferably leukemia or lymphoma, or for treating a disease selected from the group comprising acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, acute lymphoid leukemia, chronic lymphoid leukemia and myelodysplastic syndrome, and neoplasm of plasmacytoid dendritic cells (BPDNL).
RU2017129455A 2015-01-26 2016-01-25 DESIGNED IMMUNE CELLS WITH T-CELL RECEPTOR KNOCKED WITH CHIMERIC ANTIGENE RECEPTORS, BINDING WITH CD123, FOR TREATMENT OF RESIDUAL ACCIDENTS RU2017129455A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201570044 2015-01-26
DKPA201570044 2015-01-26
PCT/EP2015/055848 WO2015140268A1 (en) 2014-03-19 2015-03-19 Cd123 specific chimeric antigen receptors for cancer immunotherapy
EPPCT/EP2015/055848 2015-03-19
PCT/EP2016/051471 WO2016120220A1 (en) 2015-01-26 2016-01-25 T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm

Publications (2)

Publication Number Publication Date
RU2017129455A true RU2017129455A (en) 2019-03-04
RU2017129455A3 RU2017129455A3 (en) 2019-08-15

Family

ID=52396337

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2017129591A RU2732925C2 (en) 2015-01-26 2016-01-25 Mat-directed chimeric antigen receptor systems for sorting/depleting the engineered immune cells
RU2017129455A RU2017129455A (en) 2015-01-26 2016-01-25 DESIGNED IMMUNE CELLS WITH T-CELL RECEPTOR KNOCKED WITH CHIMERIC ANTIGENE RECEPTORS, BINDING WITH CD123, FOR TREATMENT OF RESIDUAL ACCIDENTS
RU2017129592A RU2731543C2 (en) 2015-01-26 2016-01-25 Anti-cll1-specific single-chain chimeric antigenic receptors (sccar) for cancer immunotherapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2017129591A RU2732925C2 (en) 2015-01-26 2016-01-25 Mat-directed chimeric antigen receptor systems for sorting/depleting the engineered immune cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017129592A RU2731543C2 (en) 2015-01-26 2016-01-25 Anti-cll1-specific single-chain chimeric antigenic receptors (sccar) for cancer immunotherapy

Country Status (14)

Country Link
US (6) US20180002427A1 (en)
EP (5) EP3250604B1 (en)
JP (5) JP6884709B2 (en)
KR (3) KR102329836B1 (en)
CN (5) CN107531801B (en)
AU (5) AU2016212161A1 (en)
BR (2) BR112017015453A2 (en)
CA (4) CA2973525C (en)
DK (2) DK3250606T3 (en)
ES (2) ES2842212T3 (en)
IL (3) IL252937B (en)
MX (3) MX2017009349A (en)
RU (3) RU2732925C2 (en)
WO (5) WO2016120220A1 (en)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
CN105939767B (en) 2014-01-08 2018-04-06 弗洛设计声能学公司 Sound electrophoretic apparatus with alliteration electrophoresis chamber
JP6689202B2 (en) 2014-03-19 2020-04-28 セレクティスＣｅｌｌｅｃｔｉｓ CD123-specific chimeric antigen receptor for cancer immunotherapy
RU2706582C2 (en) 2015-04-13 2019-11-19 Пфайзер Инк. Chimeric antigenic receptors aimed at antigen of aging of b-cells
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
JP2018522907A (en) * 2015-08-11 2018-08-16 セレクティスＣｅｌｌｅｃｔｉｓ Cells for immunotherapy engineered to target the CD38 antigen and to inactivate the CD38 gene
MX2018005315A (en) 2015-10-30 2018-08-14 Aleta Biotherapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER.
AU2016343805A1 (en) 2015-10-30 2018-06-07 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
CN105331586B (en) * 2015-11-20 2020-09-15 上海细胞治疗研究院 A tumor precision T cell containing a high-efficiency killing initiation mechanism and its use
CA3004743A1 (en) * 2015-11-24 2017-06-01 Cellerant Therapeutics, Inc. Humanized anti-cll-1 antibodies
HK1257295A1 (en) 2015-12-04 2019-10-18 Novartis Ag Compositions and methods for immunooncology
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
US11365237B2 (en) * 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
JP2019513836A (en) 2016-04-04 2019-05-30 ヘモジェニックス リミテッド ライアビリティ カンパニー Method of Depleting Hematopoietic Stem / Hematopoietic Progenitor Cells (HSC / HP) in a Patient Using a Bispecific Antibody
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
CA3025667A1 (en) 2016-06-08 2017-12-14 Intrexon Corporation Cd33 specific chimeric antigen receptors
JP7195154B2 (en) 2016-07-06 2022-12-23 セレクティス Sequential gene editing in primary immune cells
EP3500293A4 (en) * 2016-08-19 2020-08-19 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
WO2018057915A1 (en) 2016-09-23 2018-03-29 The Regents Of The University Of Michigan Engineered lymphocytes
EP3757120B8 (en) * 2016-10-04 2022-06-15 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
KR20190127655A (en) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. Affinity cell extraction by acoustics
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
US12269859B2 (en) 2016-12-02 2025-04-08 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
WO2018124766A2 (en) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 Chimeric antigen receptor and natural killer cells expressing same
CN108250301A (en) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 A kind of multiple target point Chimeric antigen receptor
AU2018229351B2 (en) 2017-02-28 2024-01-04 Vor Biopharma, Inc. Compositions and methods for inhibition of lineage specific proteins
EP3601561A2 (en) 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
JP7205995B2 (en) * 2017-03-29 2023-01-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antigen-binding molecules for co-stimulatory TNF receptors
PT3592379T (en) 2017-03-31 2024-05-31 Cellectis Sa Universal anti-cd22 chimeric antigen receptor engineered immune cells
KR102509006B1 (en) 2017-04-01 2023-03-13 에이브이엠 바이오테크놀로지, 엘엘씨 Replacement of cytotoxic preconditioning prior to cellular immunotherapy
JP7356354B2 (en) 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト Materials and methods for the manipulation of cells and their use in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN110831970B (en) 2017-06-02 2024-12-17 辉瑞公司 Chimeric antigen receptor targeting FLT3
CN110997920A (en) 2017-06-07 2020-04-10 英特拉克森公司 Expression of novel cell tags
CN118853581A (en) * 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 Chimeric antigen receptors (CARs), compositions and methods of use thereof
EP3645036A1 (en) 2017-06-30 2020-05-06 Cellectis Cellular immunotherapy for repetitive administration
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma Combination cancer therapy
JP7252651B2 (en) 2017-07-20 2023-04-05 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Compositions and methods for targeting CD33-expressing cancers
WO2019016360A1 (en) 2017-07-21 2019-01-24 Cellectis Engineered immune cells resistant to tumor microoenvironment
AU2018306307B2 (en) * 2017-07-25 2025-04-17 Board Of Regents, The University Of Texas System Enhanced chimeric antigen receptors and use thereof
WO2019020733A1 (en) 2017-07-26 2019-01-31 Cellectis Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection
SG11202002321YA (en) * 2017-09-27 2020-04-29 Univ Southern California Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis Improved anti-cd123 car in universal engineered immune t cells
JP7386796B2 (en) 2017-11-14 2023-11-27 グリーン クロス ラボ セル コーポレーション Anti-HER2 antibodies or antigen-binding fragments thereof, and chimeric antigen receptors comprising the same
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN109836496A (en) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 It is a kind of to target the single-chain antibody of CD317, Chimeric antigen receptor T cell and its preparation method and application
CN109837303A (en) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 A kind of Chimeric antigen receptor T cell and its preparation method and application for the targeting CD317 knocking out PD1
WO2019106163A1 (en) 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. Acoustic transducer drive and controller
WO2019129850A1 (en) 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
WO2019129851A1 (en) 2017-12-29 2019-07-04 Cellectis Method for improving production of car t cells
US20210061879A1 (en) * 2017-12-29 2021-03-04 City Of Hope Meditope-enabled t cells
CN109608548A (en) * 2017-12-29 2019-04-12 郑州大学第附属医院 Chimeric antigen receptor based on human CD20 antibody, lentiviral expression vector and its application
JP7315244B2 (en) * 2018-01-09 2023-07-26 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Compositions and methods for targeting CLEC12A-expressing cancers
PE20210708A1 (en) 2018-02-01 2021-04-16 Pfizer ANTIBODIES SPECIFIC TO CD70 AND THEIR USES
PE20252242A1 (en) * 2018-02-01 2025-09-15 Pfizer CHIMERIC ANTIGEN RECEPTORS TARGETED AT CD70
IL276831B2 (en) 2018-03-02 2025-04-01 Allogene Therapeutics Inc Inducible chimeric cytokine receptors
CN111918877A (en) * 2018-03-14 2020-11-10 美国卫生和人力服务部 anti-CD 33 chimeric antigen receptor and uses thereof
JP7551499B2 (en) * 2018-03-21 2024-09-17 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Fc variant compositions and methods of use thereof
CN108530536B (en) * 2018-03-27 2021-08-13 刘爽 CART-CD123 and its preparation and application
CN108531457A (en) * 2018-04-10 2018-09-14 杭州荣泽生物科技有限公司 A kind of method that Cas9/RNP knocks out T cell PD-1 and LAG3 gene and prepares CAR-T cells
CN112292400A (en) 2018-04-13 2021-01-29 桑格摩生物治疗法国公司 Chimeric antigen receptor specific for interleukin-23 receptor
SG11202011080QA (en) 2018-05-11 2020-12-30 Crispr Therapeutics Ag Methods and compositions for treating cancer
CN112153983B (en) * 2018-05-23 2024-09-13 杰克逊实验室 Anti-NGLY-1 antibodies and methods of use
EP3802619A1 (en) 2018-06-08 2021-04-14 F. Hoffmann-La Roche AG Peptidic linker with reduced post-translational modification
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019246593A2 (en) * 2018-06-22 2019-12-26 Fred Hutchinson Cancer Research Center Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders
EP3817767A1 (en) * 2018-07-02 2021-05-12 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
WO2020047164A1 (en) * 2018-08-28 2020-03-05 Vor Biopharma, Inc Genetically engineered hematopoietic stem cells and uses thereof
CN109503716B (en) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 A bispecific chimeric antigen receptor molecule and its application in tumor therapy
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3875484A4 (en) * 2018-10-26 2022-07-20 CRAGE medical Co., Limited ANTIBODY TARGETING CLL1 AND ITS USE
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research CANCER TREATMENT METHODS AND MATERIALS
PE20211915A1 (en) 2018-12-01 2021-09-28 Allogene Therapeutics Inc RECEPTORS OF CHEMERIC ANTIGENS TARGETING THE ANTIGEN OF RIPENING B-CELLS AND THEIR METHODS OF USE
PE20211474A1 (en) 2018-12-18 2021-08-05 Boehringer Ingelheim Io Canada Inc FLT3 AGONIST ANTIBODIES AND USES OF THEM
WO2020180591A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Dll3 targeting chimeric antigen receptors and binding agents
US12043655B2 (en) 2019-03-01 2024-07-23 Allogene Therapeutics, Inc. Constitutively active chimeric cytokine receptors
CN113518785A (en) 2019-03-01 2021-10-19 艾洛基治疗公司 Chimeric Cytokine Receptor Carrying the Extracellular Domain of PD-1
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3937974A1 (en) * 2019-03-11 2022-01-19 Leucid Bio Ltd Muc1 parallel car (pcar) therapeutic agents
JP7602803B2 (en) * 2019-03-15 2024-12-19 ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー CD147 Chimeric Antigen Receptor and Methods of Use
KR20210144679A (en) 2019-03-21 2021-11-30 알로젠 테라퓨틱스 인코포레이티드 How to Improve TCRαβ+ Cell Depletion Efficiency
CN120944827A (en) * 2019-03-27 2025-11-14 宾夕法尼亚大学董事会 Tn-MUC1 Chimeric Antigen Receptor (CAR) T cell therapy
US20220160771A1 (en) 2019-04-10 2022-05-26 Iulia Diaconu Flt3-specific chimeric antigen receptors and methods of using the same
FI3959235T3 (en) 2019-04-26 2023-09-27 Allogene Therapeutics Inc Rituximab-resistant chimeric antigen receptors and uses thereof
JP7650818B2 (en) 2019-04-26 2025-03-25 アロジーン セラピューティクス，インコーポレイテッド Methods for Producing Allogeneic CAR T Cells
JP2022531185A (en) 2019-04-30 2022-07-06 クリスパー セラピューティクス アクチェンゲゼルシャフト Allogeneic cell therapy for B cell malignancies using CD19 targeting genetically modified T cells
WO2020254591A1 (en) * 2019-06-19 2020-12-24 Julius-Maximilians-Universität Würzburg Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design
CN112111013A (en) * 2019-06-22 2020-12-22 南京北恒生物科技有限公司 Universal chimeric antigen receptor T cell targeting claudin18.2, construction method and application thereof
EP3997128A4 (en) * 2019-07-09 2023-10-18 Hemogenyx Pharmaceuticals Llc Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
AU2020336131B2 (en) 2019-08-30 2025-09-11 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising TGF beta binding domains
CA3153197A1 (en) 2019-10-03 2021-04-08 Ryan T. Gill Crispr systems with engineered dual guide nucleic acids
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
MX2022007833A (en) 2019-12-23 2022-09-23 Cellectis NEW MESOTHELIN-SPECIFIC CHEMICAL ANTIGEN RECEPTORS (CAR) FOR CANCER IMMUNOTHERAPY OF SOLID TUMORS.
TW202140533A (en) 2020-01-16 2021-11-01 美商異基因治療有限公司 Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors
EP4110805A1 (en) 2020-02-24 2023-01-04 Allogene Therapeutics, Inc. Bcma car-t cells with enhanced activities
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
JP2023517206A (en) * 2020-03-06 2023-04-24 パーデュー・リサーチ・ファウンデーション Methods, compounds and compositions for modifying CAR-T cell activity
IL296411A (en) 2020-03-16 2022-11-01 Univ Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
US20240067738A1 (en) * 2020-03-18 2024-02-29 Elanco Us Inc. Anti-il4 receptor antibodies for veterinary use
BR112022018491A2 (en) 2020-03-20 2022-11-29 Lyell Immunopharma Inc RECOMBINANT CELL SURFACE MARKERS
JP2023523890A (en) * 2020-03-27 2023-06-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Monoclonal antibodies targeting HSP70 and their therapeutic uses
CA3177093A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
US20230227525A1 (en) * 2020-05-08 2023-07-20 Smt Bio Co., Ltd. Chimeric antigen receptor for treatment of cancer
GB202007842D0 (en) * 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy
CN113735973B (en) * 2020-05-28 2023-05-09 中国科学院微生物研究所 A kind of anti-SIRPα antibody and its application
JP7760166B2 (en) * 2020-05-29 2025-10-27 ブライトパス・バイオ株式会社 Anti-CD73 antibodies and uses thereof
WO2022003158A1 (en) 2020-07-03 2022-01-06 Cellectis S.A. Method for determining potency of chimeric antigen receptor expressing immune cells
WO2022020456A2 (en) 2020-07-21 2022-01-27 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
EP4185616A1 (en) 2020-07-24 2023-05-31 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
AU2021320556A1 (en) * 2020-08-07 2023-03-09 Neogene Therapeutics B.V. Methods to enrich genetically engineered T cells
CN112079927B (en) * 2020-09-18 2021-12-28 西安桑尼赛尔生物医药有限公司 CD123 binding protein, CAR containing same and application thereof
WO2022061837A1 (en) * 2020-09-27 2022-03-31 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Fibronectin extra domain b (edb) -specific car-t for cancer
CN113234169B (en) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 Targeting CLL1 chimeric antigen receptor and its application
CN113248622B (en) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 Double-target chimeric antigen receptor targeting CLL1 and NKG2D ligands and application thereof
CN113980134B (en) * 2020-12-11 2022-05-31 广州百暨基因科技有限公司 anti-CLL1 antibodies and uses thereof
EP4259782A1 (en) 2020-12-14 2023-10-18 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CA3201115A1 (en) 2020-12-21 2022-06-30 Shanshan LANG Protease-activating cd45-gate car
MX2023007901A (en) 2020-12-31 2023-07-11 Sanofi Sa Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123.
CN112694532B (en) * 2021-01-12 2023-04-18 倍而达药业（苏州）有限公司 Antibody against Siglec-15 or antigen binding fragment thereof and application
CN112661816B (en) * 2021-01-13 2022-10-11 江西省人民医院 Artificial antigen and kit for detecting blood concentration of rituximab
MX2023008662A (en) 2021-01-28 2023-08-01 Allogene Therapeutics Inc Methods for transducing immune cells.
MX2023008809A (en) 2021-01-29 2023-08-04 Allogene Therapeutics Inc KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, ß2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS.
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CA3209863A1 (en) 2021-02-25 2022-09-01 Andrea BARGHETTI Compositions and methods for targeting, editing, or modifying genes
KR20240007179A (en) * 2021-04-30 2024-01-16 셀렉티스 에스.에이. Novel anti-MUC1 CAR and gene-edited immune cells for solid tumor cancer immunotherapy
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
WO2022266075A1 (en) 2021-06-14 2022-12-22 Caribou Biosciences, Inc. Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
WO2022266203A1 (en) 2021-06-15 2022-12-22 Allogene Therapeutics, Inc. Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence
CN115477704B (en) * 2021-06-16 2024-02-23 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on LOX1
CN115477705B (en) * 2021-06-16 2024-02-23 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on granzyme B
EP4370676A2 (en) 2021-06-18 2024-05-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
WO2023020471A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd123-targetting antibodies and uses thereof in cancer therapies
WO2023034917A1 (en) 2021-09-01 2023-03-09 Springworks Therapeutics, Inc. Synthesis of nirogacestat
CN118339187A (en) * 2021-12-31 2024-07-12 上海宏成药业有限公司 Anti-PD-1 antibodies and their uses
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
CA3244596A1 (en) 2022-03-29 2023-10-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
EP4507794A1 (en) 2022-04-11 2025-02-19 Vor Biopharma Inc. Binding agents and methods of use thereof
AU2023274452A1 (en) 2022-05-27 2025-01-16 Innate Pharma Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
CN119654406A (en) 2022-07-29 2025-03-18 艾洛基治疗公司 Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024051751A1 (en) * 2022-09-06 2024-03-14 河北森朗生物科技有限公司 Anti-cd123 nanobodies, chimeric antigen receptor, and use thereof
CA3266962A1 (en) * 2022-09-20 2024-03-28 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos
CN118240086B (en) * 2022-10-08 2025-05-09 东莞市朋志生物科技有限公司 Anti-fibrin degradation product antibody, reagent and kit for detecting fibrin degradation product
TW202440623A (en) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
WO2024121385A1 (en) 2022-12-09 2024-06-13 Cellectis S.A. Two-dose regimen in immunotherapy
WO2024238565A1 (en) 2023-05-15 2024-11-21 Vor Biopharma Inc. Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
CN117783521B (en) * 2023-11-23 2025-03-04 中国农业科学院兰州兽医研究所 Competitive ELISA kit for detecting antibodies against African swine fever virus p30 protein
CN119874909B (en) * 2023-12-21 2025-11-04 华润生物医药有限公司 Anti-TREM2 antibodies and their uses
WO2025233825A1 (en) * 2024-05-06 2025-11-13 Janssen Pharmaceutica Nv Enrichment of cells expressing a bird linker

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994024277A1 (en) 1993-04-13 1994-10-27 Sloan-Kettering Institute For Cancer Research Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1997033988A1 (en) 1996-03-12 1997-09-18 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1047770A1 (en) 2000-02-24 2003-03-07 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
ATE430161T1 (en) 2000-09-13 2009-05-15 Multimmune Gmbh PEPTIDE FROM HSP70 WHICH STIMULATES NK CELL ACTIVITY AND ITS USE
JP5312721B2 (en) 2000-11-07 2013-10-09 シティ・オブ・ホープ CD19-specific redirecting immune cells
CN1294148C (en) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
KR20050059332A (en) 2002-11-07 2005-06-17 이뮤노젠 아이엔씨 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
AR042485A1 (en) * 2002-12-16 2005-06-22 Genentech Inc HUMANIZED ANTIBODY THAT JOINS THE HUMAN CD20
EP1620537B1 (en) 2003-03-14 2012-10-24 Cellectis SA Large volume ex vivo electroporation method
EP1636265A2 (en) 2003-06-25 2006-03-22 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2005054295A2 (en) 2003-12-05 2005-06-16 Multimmune Gmbh Therapeutic and diagnostic anti-hsp 70 antibodies
DE602005022830D1 (en) * 2004-02-16 2010-09-23 Micromet Ag LESS IMMUNOGENOUS BONDING MOLECULES
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
GB0505971D0 (en) 2005-03-23 2005-04-27 Isis Innovation Delivery of molecules to a lipid bilayer
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
JP2009508517A (en) * 2005-09-22 2009-03-05 コーエン，イルン，アール Immunogenic fragments of T cell receptor constant domains and peptides derived therefrom
AU2008217579A1 (en) 2007-02-20 2008-08-28 Oxford Nanopore Technologies Limited Formation of lipid bilayers
DK2856876T3 (en) 2007-03-30 2018-04-03 Memorial Sloan Kettering Cancer Center Constitutive expression of co-stimulatory ligands on adoptively transmitted T lymphocytes
US8536310B2 (en) * 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
DE102009045006A1 (en) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 antibodies and their use for immuno-targeting in the treatment of CD33-associated diseases
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
US20130022629A1 (en) * 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
ES2754394T3 (en) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Chimeric antigen receptors with an optimized hinge region
US9487800B2 (en) 2010-09-08 2016-11-08 Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
SG189914A1 (en) * 2010-10-27 2013-06-28 Baxter Int Fviii peptides for immune tolerance induction and immunodiagnostics
SG189482A1 (en) 2010-10-27 2013-05-31 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA3179835A1 (en) 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
SG10201602159VA (en) 2011-02-11 2016-04-28 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
US8968539B2 (en) 2011-03-08 2015-03-03 Electronic Biosciences, Inc. Methods for voltage-induced protein incorporation into planar lipid bilayers
NZ743310A (en) * 2011-03-23 2022-11-25 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
US9181308B2 (en) 2011-03-28 2015-11-10 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
CA3111953C (en) 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
CA2832540C (en) 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
US9285592B2 (en) 2011-08-18 2016-03-15 Google Inc. Wearable device with input and output structures
EA201490636A1 (en) 2011-09-16 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания T-CELLS DESIGNED WITH THE HELP OF RNA FOR THE TREATMENT OF MALIGNOUS NON-FORMATIONS
KR101956751B1 (en) 2011-10-07 2019-03-11 고쿠리츠다이가쿠호진 미에다이가쿠 Chimeric antigen receptor
CN104039809A (en) * 2011-10-10 2014-09-10 希望之城公司 Meditope and meditope-binding antibodies and uses thereof
RU2644243C2 (en) 2011-10-20 2018-02-08 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Chimeric antigenic receptors to cd22
ES2861435T3 (en) 2011-11-03 2021-10-06 Univ Pennsylvania Specific compositions of isolated B7-H4 and methods of using them
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
RU2660580C2 (en) * 2011-11-15 2018-07-06 Дзе Уолтер Энд Элиза Холл Инститьют Оф Медикал Рисёч Soluble mediator
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
JP2015509717A (en) 2012-02-22 2015-04-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Use of ICOS-based CAR to enhance antitumor activity and CAR persistence
SG11201404285VA (en) * 2012-02-22 2014-10-30 Univ Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
US9783591B2 (en) 2012-02-22 2017-10-10 The Trustees Of The University Of Pennsylvania Use of the CD2 signaling domain in second-generation chimeric antigen receptors
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
KR102086874B1 (en) 2012-04-11 2020-03-10 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Chimeric antigen receptors targeting b-cell maturation antigen
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
HUE064187T2 (en) 2012-05-25 2024-02-28 Cellectis Procedure for modification of allogeneic and immunosuppressive-resistant T cells suitable for immunotherapy
CN103483452B (en) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 Dual-signal-independent chimeric antigen receptors and their uses
CA2878856A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating car t cells
EP2872526B1 (en) 2012-07-13 2020-04-01 The Trustees of the University of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
RU2663725C2 (en) 2012-09-04 2018-08-08 Селлектис Multi-chain chimeric antigen receptor and uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014130635A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
KR20150131218A (en) 2013-03-14 2015-11-24 벨리쿰 파마슈티컬스, 인크. Methods for controlling t cell proliferation
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
HK1220205A1 (en) 2013-03-15 2017-04-28 Celgene Corporation Modified t lymphocytes
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
CN105378067A (en) 2013-05-13 2016-03-02 塞勒克提斯公司 Methods for engineering highly active T cell for immunotherapy
BR112015028387B1 (en) 2013-05-13 2023-04-11 Cellectis CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR, POLYNUCLEOTIDE, EXPRESSION VECTOR, IN VITRO METHOD FOR HANDLING AND USE OF AN IMMUNE CELL
AU2014273490B2 (en) * 2013-05-29 2019-05-09 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
ES2883131T3 (en) 2013-05-29 2021-12-07 Cellectis Methods for modifying T cells for immunotherapy using the RNA-guided CAS nuclease system
KR102301464B1 (en) * 2013-06-10 2021-09-14 다나-파버 캔서 인스티튜트 인크. Methods and compositions for reducing immunosupression by tumor cells
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
MX373687B (en) 2013-11-21 2020-07-07 Ucl Business Ltd NATURAL KNOCK (NK) CELL
JP6976058B2 (en) 2013-11-22 2021-12-01 セレクティスCellectis How to Engineering Chemotherapy Drug-Resistant T Cells for Immunotherapy
US10494434B2 (en) * 2013-12-20 2019-12-03 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
CA2934436A1 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
CN106132423B (en) 2014-02-14 2020-07-31 贝里坤制药股份有限公司 Methods of activating T cells with inducible chimeric polypeptides
PT3105317T (en) 2014-02-14 2019-02-27 Cellectis IMMUNOTHERAPY CELLS HANDLED TO ACT ON ANTIGENS PRESENT IN IMMUNITY CELLS AS PATHOLOGICAL CELLS
EP3693384B1 (en) 2014-03-11 2024-01-24 Cellectis Method for generating t-cells compatible for allogenic transplantation
ES2939760T3 (en) 2014-03-15 2023-04-26 Novartis Ag Cancer treatment using a chimeric receptor for antigens
JP6689202B2 (en) * 2014-03-19 2020-04-28 セレクティスＣｅｌｌｅｃｔｉｓ CD123-specific chimeric antigen receptor for cancer immunotherapy
AU2015248956B2 (en) * 2014-04-14 2020-06-25 Cellectis BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
BR112017000939A2 (en) * 2014-07-21 2017-11-14 Novartis Ag cancer treatment using a cll-1 chimeric antigen receptor
JP7054622B2 (en) 2014-07-21 2022-04-14 ノバルティス アーゲー Treatment of cancer with humanized anti-BCMA chimeric antigen receptor
ES2688035T3 (en) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Universal antigen receptor that expresses immune cells for addressing multiple multiple antigens, procedure for manufacturing it and using it for the treatment of cancer, infections and autoimmune diseases
RU2727451C2 (en) 2014-12-05 2020-07-21 Сити Оф Хоуп T-cells modified with a chimeric antigen receptor targeting cs1
RU2706582C2 (en) 2015-04-13 2019-11-19 Пфайзер Инк. Chimeric antigenic receptors aimed at antigen of aging of b-cells
US9668192B2 (en) 2015-10-12 2017-05-30 Telefonaktiebolaget Lm Ericsson (Publ) Cell boundary crossing in a unidirectional SFN for high speed trains

Also Published As

Publication number Publication date
AU2016212160B2 (en) 2021-04-15
US20180002427A1 (en) 2018-01-04
IL253049B (en) 2022-01-01
CN107531801A (en) 2018-01-02
US20180000914A1 (en) 2018-01-04
CN107438618A (en) 2017-12-05
BR112017013981A2 (en) 2018-01-02
WO2016120216A1 (en) 2016-08-04
MX389057B (en) 2025-03-20
RU2731543C2 (en) 2020-09-04
AU2016212162A1 (en) 2017-07-13
CN113968915A (en) 2022-01-25
US20240228636A1 (en) 2024-07-11
EP3250602A1 (en) 2017-12-06
RU2017129592A3 (en) 2019-07-17
AU2016212159A1 (en) 2017-07-13
DK3250606T3 (en) 2021-01-04
IL252937A0 (en) 2017-08-31
EP3250606B1 (en) 2020-11-25
ES2842212T3 (en) 2021-07-13
JP2018504144A (en) 2018-02-15
MX381908B (en) 2025-03-13
AU2016212160A1 (en) 2017-07-13
WO2016120217A1 (en) 2016-08-04
US20180051089A1 (en) 2018-02-22
CA2973525A1 (en) 2016-08-04
CA2973524A1 (en) 2016-08-04
IL253012A0 (en) 2017-08-31
CN113968914A (en) 2022-01-25
JP2018504143A (en) 2018-02-15
KR102329836B1 (en) 2021-11-19
EP3250604A1 (en) 2017-12-06
BR112017015453A2 (en) 2018-01-23
DK3250604T3 (en) 2021-07-12
IL252937B (en) 2021-09-30
RU2017129592A (en) 2019-02-28
WO2016120220A1 (en) 2016-08-04
WO2016120219A1 (en) 2016-08-04
AU2016212158B2 (en) 2021-06-03
MX2017009349A (en) 2017-09-26
RU2017129591A (en) 2019-03-04
KR20170135822A (en) 2017-12-08
CA2973532A1 (en) 2016-08-04
CA2973525C (en) 2021-12-14
CN107531801B (en) 2021-11-12
EP3250604B1 (en) 2021-04-21
WO2016120218A1 (en) 2016-08-04
JP6779909B2 (en) 2020-11-04
US20180002435A1 (en) 2018-01-04
IL253049A0 (en) 2017-08-31
KR102661969B1 (en) 2024-04-29
RU2017129591A3 (en) 2019-08-05
CN107406516A (en) 2017-11-28
AU2016212158A1 (en) 2017-07-13
CA2973642A1 (en) 2016-08-04
JP2018504459A (en) 2018-02-15
KR20170134331A (en) 2017-12-06
EP3250605A1 (en) 2017-12-06
JP6884709B2 (en) 2021-06-09
CA2973529A1 (en) 2016-08-04
RU2017129455A3 (en) 2019-08-15
MX2017009181A (en) 2017-11-22
MX2017009182A (en) 2018-04-20
EP3250606A1 (en) 2017-12-06
BR112017014547A2 (en) 2018-01-16
JP2018504145A (en) 2018-02-15
JP2018504458A (en) 2018-02-15
US20180009895A1 (en) 2018-01-11
RU2732925C2 (en) 2020-09-24
US11014989B2 (en) 2021-05-25
CN107406516B (en) 2021-11-23
KR20170135824A (en) 2017-12-08
AU2016212161A1 (en) 2017-07-13
ES2869972T3 (en) 2021-10-26
EP3250607A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
RU2017129455A (en) DESIGNED IMMUNE CELLS WITH T-CELL RECEPTOR KNOCKED WITH CHIMERIC ANTIGENE RECEPTORS, BINDING WITH CD123, FOR TREATMENT OF RESIDUAL ACCIDENTS
JP2018504145A5 (en)
JP2016534717A5 (en)
JP2018504143A5 (en)
FI3703750T3 (en) Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
JP2016520074A5 (en)
JP2018518990A5 (en)
RU2022102250A (en) CELL
WO2017130223A3 (en) A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
RU2014118555A (en) CHIMERIC ANTIGENIC RECEPTORS TO CD22
JP2018504459A5 (en)
FI2997141T3 (en) CD19-specific chimeric antigen receptor and uses thereof
JP2018506981A5 (en)
JP2017513478A5 (en)
JP2018508219A5 (en)
JP2017515460A5 (en)
RU2015117237A (en) CHIMERA ANTIGENIC RECEPTORS M971
JP2021506243A5 (en)
RU2018107802A (en) COMPLETELY HUMAN ANTIBODIES TO MESOTELIN AND IMMUNE EFFECTIVE CELLS AIMED AT MESOTELIN
RU2017111298A (en) T-CELLS WITH COSTIMULATING CHIMER ANTIGENIC RECEPTOR AIMED AT IL13Rα2
JP2018029594A5 (en)
RU2018105963A (en) ANTIBODY AGAINST GLIPICAN-3 AND ITS APPLICATION
RU2018111462A (en) CHIMERIC ANTIGENIC RECEPTORS TARGETED ON B-CELL MATTERING ANTIGEN
JP2017537925A5 (en)
FI3708579T3 (en) CLAUDIN-6-SPECIFIC IMMUNE RECEPTORS AND T-CELL EPITOPES

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200807